NN4650
Evaluate the Safety of semaglutide in Patients with type 2 diabetes being treated with medicine similar to semaglutide.

Type of Study:
Trial evaluates 2 dose schedules for Semaglutide and the new pen-injector . Patients can not be taking Ozempic or insulin.

Study Length:
26 Weeks

Target Age/Sex:
over 18 years, Male and Female

Benefits:
Participants will receive at no cost: study product, study materials and study-specific procedures

Link: ClinicalTrials.gov

Staus: Closed

Description:

The Sustain Switch trial compares the effect and safety of 2 different dose schedules for semaglutide (study medicine) in people with type 2 diabetes previously treated with a diabetes medicine similar to semaglutide.

This Study is Closed.